部署一揽子稳增长举措 为了推动经济实现良好开局，春节前后，安徽、辽宁、河南、福建、黑龙江、云南等地密集部署了推动 一季度经济稳增长的政策举措，着力促消费、强产业、惠民生。 在需求端，促消费和扩投资是各地提到的重点。安徽日前提出，在提振消费方面，将制定居民增收方 案、完善工资增长机制，培育新型消费场景等；河南出台的若干政策提到，统筹推进交通、能源、水利 等重大基础设施建设，开工沙颍河"通港达园"工程等一批重大项目。 在产业端，强调要加快推动产业升级、发展未来产业。安徽明确，深入实施新兴产业集群发展工程，统 筹安排41亿元用于培育壮大新动能；福建提出，培育打造数据产业集聚区和数据要素产业园，推进国家 数据产业集聚区建设试点。 开春即冲刺。春节假期过后，山西、陕西、山东、北京等地吹响了重大项目建设"开工号"，安徽、辽宁 等地发布稳经济的专项政策举措。多地以务实举措促投资、扩内需、稳增长、促转型，努力为"十五 五"开好局、起好步。 吹响重大项目建设"开工号" 春节假期后，在位于山西转型综改示范区的山西纳安生物科技股份有限公司，上海证券报记者看到公司 智能化生产线扩建项目已全面铺开，全自动包装机组、全自动灌装流水线等核 ...

（来源：衢州日报） 转自：衢州日报 本报讯 （记者 徐颖之） 人勤春来早，功到秋华实。2月25日至26日，衢州市新春第一会刚结束，市委 书记高屹即率队赴苏州开展招商考察活动，走访考察多家行业头部企业，深化对接合作，加快项目落 地，进一步激发全市上下"大抓工业、大抓产业"的拼劲干劲，为"十五五"开好局起好步提供坚实支撑。 项目是工业强市的硬支撑。普洛斯数据中心控股平台总部项目已落地衢州，是衢州迄今为止引进的最大 外资项目、最大服务业项目。高屹考察苏州普洛斯物流园、环普苏桐112国际科创园，与企业负责人座 谈，介绍过去一年衢州经济社会发展情况，就加快在衢项目建设、深化政企合作等进行深入交流。他 说，衢州正深入实施"工业强市、产业兴市"战略，大力推动"五链"深度融合，着力构建"612X"先进制造 业集群，加快打造产业链关键企业最容易落地、最适宜发展的城市。希望普洛斯深耕衢州，充分发挥资 金、技术、管理、人才等优势，进一步加大新兴产业、未来产业投资布局力度，牵引更多高端要素涌入 衢州、发展衢州，实现双向奔赴、相互赋能。衢州将竭尽所能为企业发展提供更好环境、更优服务，努 力让企业在衢州安心经营、放心投资、专心发展。 高 ...

Nautilus Biotechnology (NasdaqGS:NAUT) Q4 2025 Earnings call February 26, 2026 08:30 AM ET Company ParticipantsAnna Mowry - CFOJi-Yon Yi - Director of Investor RelationsParag Mallick - Co-founder and Chief ScientistSujal Patel - Co-founder and CEOConference Call ParticipantsSubhasis Nambi - Equity Research AnalystNone - AnalystOperatorGood day, and thank you for standing by. Welcome to the Nautilus Biotechnology Q4 2025 earnings conference call. At this time, all participants are in a listen-only mode. Afte ...

过去一年，经济和资本市场向好，加上强化版财政整合计划渐见成果，香港公共财政状况改善较预期 快，提前由亏转盈。据预计，2025/2026年度综合账目将由原来预算约670亿港元赤字，转为录得29亿港 元盈余。 特区政府财政司司长陈茂波在预算案中提出一系列打造国际创新科技中心的措施，包括提速AI推动产 业化、建设北都国际创科新城、培育与壮大新兴产业等。 来源：新华社 新华社香港2月26日电 香港特区政府2026/2027财政年度财政预算案25日出炉。各界人士认为，预算案 主动对接国家"十五五"规划建议，从"AI（人工智能）+"和"金融+"两条主线推进，将进一步加强香港的 核心竞争力，增强经济动能，扎实推动香港经济提速增量。 香港特区立法会议员邱达根注意到，预算案将航天科技、具身智能等前沿领域纳入发展蓝图，展现特区 政府对新兴科技趋势的敏锐把握，以及全面对接国家"十五五"规划的决心。 香港科学院及香港青年科学院表示，预算案与国家"十五五"规划建议高度对接，同频发展，既能进一步 落实香港国际创新科技中心的定位，也能充分发挥香港背靠祖国、联通世界的独特优势，助力香港汇聚 全球顶尖研发团队与高端科技人才，让创科成为香港未来 ...

Core Viewpoint - The Chinese innovative pharmaceutical sector is experiencing a downturn in stock indices, yet there is significant capital inflow into innovative drug ETFs, indicating a potential investment opportunity in the long term [1]. Group 1: Market Performance - The CSI Hong Kong Stock Connect Healthcare Comprehensive Index fell by 4.7%, while the Hang Seng Hong Kong Stock Connect Innovative Drug Index decreased by 4.3% [1]. - The CSI Innovative Drug Industry Index declined by 1.5%, and the CSI Biotechnology Theme Index dropped by 1.2% [1]. - The CSI 300 Healthcare Index saw a smaller decline of 0.8% [1]. - Despite the overall market downturn, the E Fund Hong Kong Stock Connect Innovative Drug ETF (159316) recorded a net subscription of 34 million units throughout the day [1]. Group 2: Industry Growth and Valuation - The total value of License-out transactions for Chinese innovative drugs has increased from $2.562 billion in 2017 to $140.274 billion by 2025, reflecting enhanced international competitiveness [1]. - By 2025, over 70% of innovative drug companies are expected to achieve positive revenue growth, indicating that the industry is entering a commercialization phase [1]. - The current valuation of the pharmaceutical sector is considered attractive, with recommendations to focus on companies with clear overseas expansion opportunities and those with clinical data advantages in specific segments [1].

专题：《钱道》：对话上市公司掌门人 在对话中，谈及一个组织衰老的致命原因时，华熙生物董事长赵燕表示，组织和生命体是一样的，组织 的衰老是源于领导者将过往的经验带到了这个组织当中，但是环境变了，经验没有跟着变化。 赵燕特别指出，尤其是成功的企业，他们抱着"我这条路径是成功的"想法，产生了路径依赖，不去看外 部环境发生了哪些变化，消费者发生了哪些变化。她以华熙生物为例，谈到华熙生物是一家创新驱动的 企业，按道理来说，它对前沿的东西应该是最敏锐的，而且对于消费者市场的需求，也应该是最敏锐 的。一定要时时刻刻保持观察到消费者未被满足的需求在哪，而不是去跟风市场上的需求。 "衰老是能传染的，组织内部尤其这样。一旦出现了这样的现象，一个小点就能扩散到一条线，一条线 就能扩展到一个面。"她说。 由@新浪财经、微博联合打造，@微博财经 #达芬奇live# 出品的对话栏目#钱道# 第一期，邀请华熙生 物董事长赵燕，与英才元投资管理有限公司董事长@宋立新 在15分钟精华对话中，坦诚分享如何识别 组织衰老、推动认知对齐、重建执行逻辑。#透过财经看世界# 新浪声明：所有会议实录均为现场速记整理，未经演讲者审阅，新浪网登载此文出于传递 ...

在对话中，谈及衰老的话题，华熙生物董事长赵燕坦言，"每个人对衰老都有担忧，但是我不害怕。" 赵燕表示，大家都认为衰老是一个自然过程，但是在生命科学领域来说，衰老是能够被主动干预和控制 的过程。容颜的衰老它只是一个表面，要更关注"生命的延长"，怎么样有质量地活得长。 她提到，女人有"三怕"：怕老、怕丑、怕死。随着生命科学的发展，这三个方面都是能够去有效地控制 的。华熙生物的使命，是让每个生命都是鲜活的，所以要提高生命质量，让人活得长。"医美说到底， 是让人重拾自信，尤其对于女性，能够很优雅地变老，更多的是一个心理上的慰藉。" 由@新浪财经、微博联合打造，@微博财经 #达芬奇live# 出品的对话栏目#钱道# 第一期，邀请华熙生 物董事长赵燕，与英才元投资管理有限公司董事长@宋立新 在15分钟精华对话中，坦诚分享如何识别 组织衰老、推动认知对齐、重建执行逻辑。#透过财经看世界# 新浪声明：所有会议实录均为现场速记整理，未经演讲者审阅，新浪网登载此文出于传递更多信息之目 的，并不意味着赞同其观点或证实其描述。 专题：《钱道》：对话上市公司掌门人 责任编辑：李昂 专题：《钱道》：对话上市公司掌门人 责任编辑：李昂 在 ...

Group 1 - The pharmaceutical sector is experiencing significant growth, with BD transaction volumes reaching new highs and domestic innovative drugs gaining international recognition, making it a focal point for investors [1][3] - However, there is a growing fatigue regarding the expectations for innovative drugs going abroad, leading to a shift from a "highlight moment" to a "volatile adjustment" in the market [2][3] - This transition is viewed as a necessary step towards a long-term market trend, with signs of recovery in the pharmaceutical sector as it approaches a new cycle starting in 2026 [3][11] Group 2 - The current investment rationale in the pharmaceutical sector is supported by three main forces: demand, supply, and policy, which are converging to fuel a new round of growth [5][36] - Demand for healthcare is increasing due to an aging population and rising health awareness, transforming medical consumption from optional to essential [6][37] - The supply side shows that China's innovative drugs are becoming globally competitive, with the number of innovative drug pipelines accounting for nearly 30% of the global total and BD overseas licensing transactions reaching $135.7 billion in 2025, a 161% increase year-on-year [7][38] Group 3 - Policy changes are shifting from cost control to empowerment, with new measures introduced to support the entire chain of innovative drug development, access, usage, and payment [10][41] - The Hong Kong stock market is becoming a primary platform for Chinese innovative drug companies due to its flexible listing regulations and foreign investment environment, which has attracted over 70 competitive innovative drug and CXO companies [12][43] - The establishment of the Hong Kong Medical Device Regulatory Center (CMPR) and other supportive mechanisms is expected to enhance the internationalization and business development capabilities of companies listed in Hong Kong [13][44] Group 4 - The Hang Seng Biotechnology Index has outperformed other indices with a 82.75% increase, highlighting its strong market position [16][46] - The index is composed of the top 30 biotechnology companies, focusing on high-growth sectors such as innovative drugs (79% weight) and CXO services (11% weight), ensuring coverage of the core segments of the pharmaceutical industry [17][49] - The index's unique feature includes being the only pharmaceutical-themed index in Hong Kong equipped with index futures, providing risk management tools and enhancing liquidity for investors [23][54] Group 5 - The Hang Seng Biotechnology Index is currently at a historically low valuation, with a PE ratio of 30.01, significantly lower than the NASDAQ Biotechnology Index and the CSI Biotechnology Index, indicating a valuation advantage [26][55] - The index's components are primarily leading innovative drug and CXO companies with solid R&D capabilities, suggesting potential for steady profit release as pipelines mature and orders are fulfilled [28][57] - The current market conditions may present a favorable opportunity for long-term investors to allocate resources into high-quality pharmaceutical assets through the Hang Seng Biotechnology ETF [29][58]

Core Viewpoint - The Beijing-Tianjin-Hebei (Jing-Jin-Ji) coordinated development is transitioning from planning to practical implementation, with significant impacts on tourism and local economies driven by cultural and tourism integration [5][6]. Group 1: Cultural and Tourism Integration - The integration of cultural and tourism industries in Tongzhou, Wuqing, and Langfang is a vibrant aspect of Jing-Jin-Ji development, creating unique tourism IPs that cater to diverse consumer needs and facilitate mutual customer flow [6][9]. - Universal Studios Beijing has become a major tourist destination, significantly boosting local industries such as hospitality and transportation, with a reported GDP multiplier effect of 6:1 for every yuan spent in the park [6][7]. - The Bay Area project near Universal Studios achieved over 3 billion yuan in sales within its first month, with more than 35% of visitors coming from outside Beijing, indicating strong regional tourism appeal [7]. Group 2: Transportation Connectivity - A comprehensive transportation network supports the Jing-Jin-Ji coordinated development, creating an "hourly living circle" that enhances mobility and resource sharing among Tongzhou, Wuqing, and Langfang [10][11]. - The integration of road, rail, and water transport has improved commuting efficiency, exemplified by high-speed rail facilitating daily cross-regional travel for professionals [10][11]. - Upgrades to key transportation nodes, such as inspection stations, have significantly improved traffic flow and reduced wait times, enhancing the overall commuting experience [13][14]. Group 3: Mechanism Innovation - The Beijing Daxing International Airport Economic Zone exemplifies innovative management mechanisms that break down administrative barriers, fostering a collaborative development model between Beijing and Hebei [16][18]. - Policy coordination has enabled seamless service delivery across regions, with numerous administrative processes streamlined for efficiency, supporting industrial integration [16][17]. - The economic zone has attracted significant investment and projects, demonstrating the effectiveness of cross-regional collaboration in enhancing economic dynamism [17][18].

玮俊生物科技(00660)发布公告，集团预期于截至2025年12月31日止六个月取得的净亏损不超过600万港 元，亏损相比截至2024年12月31日止六个月的净亏损约1310万港元大幅减少。亏损大幅减少的主要原因 为报告期内营业额的上升及财务成本的减少。 ...